Table 6 OR with 95% CI for iORR (lower triangle) and iDCR (upper triangle) in patients with EGFR-mutant NSCLC and brain metastases.

From: First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

1G EGFR-TKIs

0.80 (0.21–3.11)

1.02 (0.26–3.95)

1.46 (0.27–7.79)

0.30 (0.14–0.64)*

1G EGFR-TKIs + CT

1.28 (0.19–8.68)

1.82 (0.21–15.76)

0.49 (0.35–0.70)

1.63 (0.71–3.78)

3G EGFR-TKIs

1.43 (0.53–3.84)

0.41 (0.21–0.81)*

1.37 (0.50–3.80)

0.84 (0.47–1.50)

3G EGFR-TKIs + CT

  1. OR: odds ratio; CI: confidence intervals; iORR: intracranial objective response rate; iDCR: intracranial disease control rate; NSCLC: non-small cell lung cancer; 1G/3G EGFR-TKIs: first/third-generation epidermal growth factor receptor tyrosine kinase inhibitors; CT: chemotherapy.
  2. *Represents a statistically significant difference in OR values
Back to article page